Russell Investments Group Ltd. Sells 46,276 Shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE)

Russell Investments Group Ltd. decreased its position in shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) by 55.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,004 shares of the biopharmaceutical company’s stock after selling 46,276 shares during the quarter. Russell Investments Group Ltd.’s holdings in Xenon Pharmaceuticals were worth $332,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its holdings in shares of Xenon Pharmaceuticals by 8.8% during the second quarter. Point72 Asset Management L.P. now owns 925,000 shares of the biopharmaceutical company’s stock valued at $9,121,000 after acquiring an additional 75,000 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Xenon Pharmaceuticals by 55.5% during the second quarter. Northern Trust Corp now owns 37,636 shares of the biopharmaceutical company’s stock valued at $371,000 after acquiring an additional 13,434 shares in the last quarter. NEA Management Company LLC bought a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $1,802,000. Supplemental Annuity Collective Trust of NJ bought a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $99,000. Finally, Altshuler Shaham Ltd increased its holdings in shares of Xenon Pharmaceuticals by 4.3% during the second quarter. Altshuler Shaham Ltd now owns 149,758 shares of the biopharmaceutical company’s stock valued at $1,477,000 after acquiring an additional 6,151 shares in the last quarter. Hedge funds and other institutional investors own 62.24% of the company’s stock.

XENE has been the subject of several recent research reports. Guggenheim initiated coverage on Xenon Pharmaceuticals in a report on Friday, September 20th. They set a “buy” rating and a $25.00 price objective for the company. Zacks Investment Research upgraded Xenon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a report on Saturday, October 26th. Finally, ValuEngine downgraded Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Xenon Pharmaceuticals has an average rating of “Buy” and an average target price of $17.67.

In related news, Director Frank A. Holler sold 7,600 shares of the stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $9.27, for a total transaction of $70,452.00. Following the sale, the director now owns 124,161 shares of the company’s stock, valued at approximately $1,150,972.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Simon N. Pimstone sold 10,395 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $9.51, for a total value of $98,856.45. Following the completion of the transaction, the chief executive officer now owns 258,122 shares in the company, valued at $2,454,740.22. The disclosure for this sale can be found here. In the last three months, insiders sold 23,087 shares of company stock worth $216,766. Insiders own 8.35% of the company’s stock.

Shares of Xenon Pharmaceuticals stock opened at $11.83 on Monday. The stock has a fifty day simple moving average of $9.09 and a 200 day simple moving average of $9.38. Xenon Pharmaceuticals Inc has a 12-month low of $5.41 and a 12-month high of $12.48. The company has a market capitalization of $297.23 million, a P/E ratio of -8.89 and a beta of 1.31. The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.18.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.16. The company had revenue of $3.50 million for the quarter. On average, analysts predict that Xenon Pharmaceuticals Inc will post -1.66 EPS for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Recommended Story: How dollar cost averaging works

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.